
SELLAS Life Sciences (NASDAQ: SLS) shares surged more than 281%, climbing above $28 on trading volume exceeding 200 million shares after the company announced positive results from its pivotal Phase 3 REGAL trial. The trial showed a statistically significant and clinically meaningful improvement in overall survival among patients with acute myeloid leukemia (AML) treated with its cancer vaccine, Galinpepimut-S (GPS). The results could trigger significant short covering, with 57.1 million SLS shares sold short as of October 30, representing 28% of outstanding shares. However, analysts warn that a potential stock offering to fund regulatory filings and commercialization could limit further gains and reduce short-squeeze momentum.
Goldman Sachs forecasts gold prices to reach $4,650 per ounce by the end of 2027…
Home Depot (NYSE: HD) shares fell around 2% in pre-market trading despite beating Wall Street…
A crypto trader checking in at any hour may want to know how close their…
Most of the Magnificent 7 stocks traded lower, with Nvidia (NVDA) gaining 1%, Amazon (AMZN)…
A trade can move in your favour and still leave you with a loss. The…
Nvidia will report its third-quarter fiscal 2027 earnings on Tuesday, November 17, 2026, after the…